


CANCER
RESEARCH
HORIZONS

FURTHER FASTER TOGETHER

OUR BUSINESS
IS BREAKTHROUGHS

ACCELERATING DISCOVERIES
FOR PATIENT BENEFIT



WORK IN ONE OF THE BELOW? READ ON TO FIND OUT HOW WE CAN HELP YOU MEET YOUR GOALS



THERAPEUTIC
DISCOVERY



CLINICAL
DEVELOPMENT



STARTUPS AND
INVESTMENTS



STRATEGIC
DEVELOPMENT
INITIATIVES



LICENCES AND
COLLABORATIONS

WHO ARE WE?

Cancer Research Horizons is the innovation arm of Cancer Research UK, the largest independent funder of cancer research in the world. Established in 2002, Cancer Research UK funds about £300+ million of academic research each year within a network of over 4,000 researchers, clinicians and nurses.

Funding world-class research for decades has greatly broadened our understanding of cancer and how to diagnose and treat it and led to millions of people benefitting from innovations translated from Cancer Research UK-funded discoveries.

However, too few of these discoveries progress from the bench to the bedside, stalling in the translational gap. New technology and drug development requires a huge amount of investment, and at the early stages these investments are high risk.

That is where Cancer Research Horizons dwells. With direct access to Cancer Research UK's research, infrastructure and commercialisation expertise, we are uniquely placed to fast-track scientific breakthroughs for patient benefit.

We offer the full spectrum of drug discovery and clinical capabilities, as well as translational funding, licensing opportunities, and support for startups.

Our business is breakthroughs.



OUR UNIQUE APPROACH



EMBRACE NOVELTY

We work with researchers and industry to identify and advance novel therapeutic approaches underpinned by deep biological expertise.



EMBODY TEAM SCIENCE

We put collaboration at the centre of discovery by bringing together synergistic teams of world-class cancer researchers and clinicians.



PARTNER AT SCALE

We work with like-minded organisations to leverage novel capabilities and accelerate the delivery of first-in-class, breakthrough therapies.



LEVERAGE OUR NETWORK

We have unparalleled access to world-leading cancer researchers and clinicians through Cancer Research UK's network.

OUR TRACK RECORD



11
marketed drugs



£2.8bn
raised by our spinout and start-up portfolio



£526M
revenue from royalties & IP



60+
spinouts & start-ups



6M+
courses of treatment for cancers through
drugs that we have directly helped to market



#2
largest oncology
out-licensor globally



160
new drugs into early-phase clinical trials




150
active licences

OUR NETWORK

We have unparalleled access to the UK's most innovative cancer science.

We support a thriving UK-wide ecosystem with capabilities across the research and translational pipelines, from basic biological research to the delivery of late-phase clinical trials.



- Institutes (4)
- Centres (7)
- Lung Cancer Centre of Excellence (1)
- Brain Tumour Centre of Excellence (2)
- Experimental Cancer Medicine Centres (ECMCs) Adult and Paediatric (9)
- Experimental Cancer Medicine Centres (ECMCs) Adult (9)
- Experimental Cancer Medicine Centres (ECMCs) Paediatric (2)
- Clinical Trials Units (8)
- Cancer Research Horizons Drug Discovery Facilities (4)
- Cancer Research Horizons-AstraZeneca Antibody Alliance Laboratory (1)
- Cancer Research Horizons-AstraZeneca Functional Genomics Centre (1)
- Manufacturing Facility (1)
- RadNet (7)
- International Alliance for Cancer Early Detection (ACED) (3)
- National Cancer Imaging Translational Accelerator (NCITA) (9)


LONDON

- | | |
|--|--|
| Barts | King's College London |
| ● ECMC | ○ NCITA |
| CRUK City of London Centre (KCL, UCL, Barts, the Crick) | King's Health Partners |
| ○ Centre | ● ECMC |
| ● RadNet | ● Clinical Trials Unit |
| CRUK Convergence Science Centre (ICR-Imperial) | The Francis Crick Institute |
| ○ Centre | ○ Institute |
| Imperial | ● Cancer Research Horizons Drug Discovery Facility |
| ● ECMC | UCL |
| ○ NCITA | ○ ACED |
| Institute of Cancer Research (joint with Cambridge) | ○ Brain Tumour Centre of Excellence (joint with Edinburgh) |
| ○ Brain Tumour Centre of Excellence (joint with Cambridge) | ● Clinical Trials Unit |
| ● Clinical Trials Unit | ● ECMC |
| ● ECMC | ○ Lung Cancer Centre of Excellence (joint with Manchester) |
| ● RadNet | ○ NCITA |
| ○ NCITA | |

OUR NETWORK



By identifying and bringing together world class research teams from across our Network we complement our translational drug discovery capabilities with unique cancer-focused expertise & insights.



FROM DISCOVERY RESEARCH TO CLINICAL DEVELOPMENT



Cancer Research Horizons offers partners expertise and capabilities along the entire translational development continuum from academic research discovery to clinical application by streamlining the connections between the three divisions: Therapeutic Innovation, Commercial Partnerships, and Cancer Research UK's Centre for Drug Development (CDD).



Therapeutic Innovation

Our Therapeutic Innovation division, accelerates new therapeutics from target discovery to clinical candidates. This drug discovery organisation spans across six sites within world-leading academic and biopharma hotspots, including the Beatson Institute (Glasgow), the Francis Crick Institute (London), Newcastle University, and Babraham Research Campus (Cambridge) and brings together over 200 scientists with expertise and capabilities encompassing deep cancer biology knowledge and extensive translational drug discovery technology platforms and experience.



Commercial Partnerships

Our Commercial Partnerships division deals with all business development activities, including managing intellectual property, providing a spectrum of translational funding (such as early-detection, data-innovation, and therapeutic-catalyst awards to progress drugs, devices, diagnostics, data and software), supporting all partnerships, and facilitating startups.



Centre for Drug Development

For clinical development, CRUK's Centre for Drug Development (CDD) encompasses 30 years' experience of successfully converting research ideas into novel therapies, and a portfolio rivalling that of a medium-sized pharmaceutical company. CDD provides the development capabilities, expertise and infrastructure—including manufacturing and drug supply, preclinical activities, regulatory interactions, and early-phase clinical trials—to accelerate preclinical and early clinical development of innovative candidates.

OUR PARTNERS

We provide unparalleled access to CRUK's innovative science portfolio & are the gateway for partners to connect with our cancer expertise, R&D capabilities, & enabling infrastructure across the CRUK Network.

.....

LICENSES & COLLABORATIONS
STARTUP FORMATION & INVESTMENT
THERAPEUTIC DISCOVERY ALLIANCES
CLINICAL DEVELOPMENT PARTNERSHIPS
STRATEGIC R&D INITIATIVES



OUR PARTNERSHIP MODELS



Our Commercial Partnerships division builds partnerships with the biopharmaceutical industry under a variety of flexible models:

- **Intellectual property licensing** – we have exclusive rights to all intellectual property arising from Cancer Research UK-funded discoveries
- **Therapeutic Discovery Alliances** – we forge customised, multi-project alliances with industry and investors to support translation around themed areas of biology
- **Clinical Development Partnerships** – we offer biopharma companies resources, capabilities and expertise to develop new agents for cancer treatment
- **Startups** – we facilitate company creation where the advance of a potential treatment would be best served by being placed in a startup environment

We also provide entrepreneurial programmes to help researchers translate their work, coupled with a spectrum of translational funding awards to give them the money to do so.

On top of that, the Cancer Research Horizons Seed Fund offers investment in promising, early-stage opportunities from within the Cancer Research UK network and beyond to continue to grow our portfolio of successful startup companies.

The Seed Fund currently stands at £15m, which we aim to increase to £30m.

Any financial returns we generate are reinvested back into the fund. Investment decisions are made based on the potential to leverage and attract high-quality follow-on capital that will increase the chances of life-saving cancer treatments and diagnostics reaching the market.

OUR NEW INTERNATIONAL PARTNERSHIPS



Oncode Institute

MAY 22

JULY 22

Deep Science Ventures

Karolinska Institute

Astex Pharmaceuticals

NOVEMBER 22

Envisagenics,
Queen Mary
University of
London

Novartis

DECEMBER 22

Singapore's
Experimental Drug
Development
Centre

Predictive
Oncology

UCB

MARCH 23

SPOTLIGHT: INTERNATIONAL PARTNERSHIPS




Karolinska Institutet

We're partnering with the Karolinska Institutet, a world-leading medical university in Sweden, to enable the validation and translation of novel targets and mechanisms. We have committed to joint activities including research collaborations, theme-based alliances, and mutual access to facilities, expertise and tools.



Our partnership with Singapore's Experimental Drug Development Centre, hosted by the Agency for Science, Technology and Research (A*STAR), reflects our commitment to international collaboration. We will leverage our complementary capabilities to accelerate oncology pipeline assets across a range of developmental stages.



Oncode Institute

Under our strategic alliance with the Oncode Institute in the Netherlands we will focus on early-stage oncology to de-risk novel ideas and pursue relatively unexplored areas of cancer research. We will develop joint training programmes for researchers and share drug discovery capabilities.

SPOTLIGHT: COLLABORATIONS & ALLIANCES



Our long-term alliance with Astex Pharmaceuticals and Newcastle University brings together the innovative small-molecule drug development capabilities of the former and the world-leading medicinal chemistry researchers of the latter.


The alliance includes multiple projects across target validation and early-stage hit-identification, and has already resulted in the identification of an MDM2-p53 antagonist compound (ASTX295) which has entered clinical evaluation.

Our collaboration with UCB unites their renowned antibody discovery expertise with the clinical development capabilities of Cancer Research UK's Centre for Drug Development to focus on two investigational antibody candidates, UCB6114 and UCB4594.

UCB6114 is a potential first-in-class antibody targeting gremlin-1, a glycoprotein secreted by the tumour stroma. UCB4594 is an antibody targeting the immune checkpoint, human leukocyte antigen G (HLA-G).

THERAPEUTIC DISCOVERY

with Cancer Research Horizons



OUR THERAPEUTIC DISCOVERY CAPABILITIES



Our drug discovery division has expertise and capabilities in translating early concepts into therapeutic innovation, encompassing deep cancer biology knowledge and extensive translational drug discovery experience.

PROGRESS TOWARDS THE CLINIC



TARGET ID & VALIDATION

We align targets with a clearly defined clinical position as early as possible.

- ✓ CRISPR screening to identify novel targets.
- ✓ A world-class human immunology platform
- ✓ Cellular models, including organoids and patient-derived tissue explants



HIT DISCOVERY

We drive project progression from early hit identification through to detailed mechanism-of-action studies.

- ✓ Specific strengths in HTS and fragment-based drug discovery,
- ✓ Clear focus on profiling against the most physiologically-relevant endpoint possible.



HIT TO CANDIDATE

We use our experience in mechanistic pharmacology, medicinal chemistry, DMPK and in vivo cancer models to progress our projects towards efficacy studies.

- ✓ Computational chemistry
- ✓ Structural insights,
- ✓ Analysis of SAR biology
- ✓ drug-target kinetics
- ✓ synthetic chemistry
- ✓ ADME profiling

PARTNERING TO DRIVE THERAPEUTIC DISCOVERY



INPUT

Our Network

In-depth biological expertise, novel targets, disease models and patient samples.

Our Capability & Expertise

200+ drug discovery scientists & leaders, access to KOLs & dedicated alliance management support.

Our Infrastructure

Four drug discovery sites set against a backdrop of nationwide translational infrastructure.

Your Resource

Upfront investment (R&D costs), research and development capabilities, pipeline candidates.



PARTNERSHIP

Industry discovery alliance

Partnership designed to harness complementary capabilities, expertise & infrastructure with the ambition to co-create a portfolio of first-in-class therapies that synergises with our partners' pipeline.

NewCo formation & incubation

Company creation & initial operationalisation undertaken by CRH to fast-track early-stage novel science into therapeutic innovations & attract onward investment to drive maximum patient benefit.

Risk-Share Partnership

We develop your asset at our own risk through deployment of our network, capabilities and infrastructure to take your asset to the next value inflection point.



OUTPUT

Delivery of Novel Agents

Multi-project discovery portfolios, delivery of development candidates.

Internalise & Progress

Industry partner has option to internalize projects at predefined stage (candidate/Phase 1).


Fair return

CRH receives financial return (milestone, royalties) if projects are successfully developed.

Patient benefit

LICENSES & COLLABORATIONS

with Cancer Research Horizons



LICENSING PRINCIPLES



OUR DRIVER

Our commercialisation priorities are focused on delivering maximum patient benefit



RESERVED RESEARCH RIGHTS

We reserve the right to practice licensed IP and publish research and information



IP DEVELOPMENT

We seek licensee commitment to the diligent development of licensed IP



EFFECTIVE PARTNERSHIPS

We identify and cultivate productive relationships with companies that share our values



FAIR FINANCIALS

We seek financial return to CRUK commensurate with development stage and value proposition to reinvest in cancer research




RISK MANAGEMENT

We mitigate our exposure to commercialisation risks associated with the development and sale of licensed IP

STARTUPS & INVESTMENTS

with Cancer Research Horizons



OUR STARTUPS



We bring early-stage technologies out of the research lab and translate them into patient benefit.

Our startup portfolio secures funding from investors around the world who believe in our world class science and the power of partnership.

>60
STARTUPS

£2.8B
CAPITAL
RAISED

ACTIVE



EXITED



AND MANY MORE

INVESTMENT OPPORTUNITIES



To accelerate development of opportunities across cancer therapeutics, diagnostics, medtech and AI, we partner with investors under a variety of traditional and innovative models:

- **Invest** in opportunities arising from Cancer Research UK-funded research including single-asset, multi-asset and platform technologies
- **Co-invest** via our Cancer Research Horizons Seed Fund to accelerate the commercial development of cancer-focused research and startups
- **Create co-ventures**, including through our new therapeutic innovation offering
- **Partner with portfolio companies**, leveraging the intellectual input and infrastructure of our expert network for mutual benefit

We want to connect with seed and series A-focused


funds to create and grow new companies, and add to our established track record. Over the years, we've been involved in forming and developing more than 60 startups, which have raised total capital of over £2.3 billion to date.

Our active startups include:



CLINICAL DEVELOPMENT

with Cancer Research Horizons



OUR EXPERIENCE & TRACK RECORD



We have extensive clinical development experience with a proven track record of delivering early phase trials.



160

Early phase trials delivered



60+

agents taken in to first-in-human trials



15

active programmes in our current portfolio



100

CTA application success rate the MHRA



6

agents registered as medicines



30

collaborations under the CDP initiative



OUR APPROACH



Our Centre for Drug Development partners with innovators in science and medicine to deliver more treatment options to cancer patients.



CENTRE OF EXCELLENCE

Our drug development capabilities & expertise & infrastructure allows us to dem, together with our network of investigators onstrate clinical potential.



PARTNERSHIPS

We collaborate with industry partners under a shared risk reward model to provide a capital efficient route to progress the development of cancer therapies.



INNOVATION

We are motivated by delivering patient benefit, focusing on innovative, first-in-class agents and science-driven first-in-human trials.

OUR CAPABILITIES & EXPERTISE



Our team of over 100 clinical development experts advance promising cancer therapeutic programmes from candidate selection to early clinical proof of concept.



CMC AND DRUG SUPPLY

- Pharmaceutical development
- Drug product manufacture
- Drug supply chain management



PRECLINICAL ACTIVITIES

- CTA (IND)-enabling studies
- PK & PD assay development
- Trial design & protocol development
- Supporting translational research



REGULATORY INTERACTIONS

- Scientific advice meetings
- CTA document preparation
- CTA application submission



EARLY PHASE CLINICAL TRIALS

- ICH GCP trial sponsorship
- Site selection & feasibility
- Clinical trial management
- Data/base management

OUR CLINICAL NETWORK

Our capabilities and expertise, together with our network of centres and investigators make us a partner of choice.

WORLD-CLASS INVESTIGATORS


Leverage CRUK's network of scientific and clinical investigators to design, sponsor and deliver science-driven clinical development.

UNIQUE CLINICAL INFRASTRUCTURE

Experimental Cancer Medicine Centres (ECMCs) integrating NHS hospitals and research institutions.

NATIONAL HEALTH SERVICE INTEGRATION

Multi-centre trials delivered across network of 20 clinical centres, providing access to a broad UK adult and paediatric patient population.



OUR CLINICAL PARTNERSHIPS

We collaborate with leading industry partners to advance the clinical development of promising cancer therapeutics.

CLINICAL DEVELOPMENT PARTNERSHIP

We collaborate with our partner to design, setup & deliver a CRUK-sponsored clinical trial via our UK-wide network.

IP AND CLINICAL TRIAL DATA

Our partners retain their background IP & receive a licence to the clinical trial results & all collaboration IP.

SHARED RISK REWARDS

Our partnerships are undertaken on a shared risk reward basis offering capital efficient clinical development.

FUNDING AND FINANCIAL TERMS

We aim to recover a portion of our costs during the partnership & receive a fair share of future revenues if the agent is successful



33 PARTNERSHIPS TO DATE

11 (+1)
ACTIVE PARTNERSHIPS

8
ACTIVE LICENCES



FURTHER FASTER TOGETHER

PARTNER WITH US

cancerresearchhorizons.com



Andrea Schievella
Head of Business Development, Cancer Research Horizons Boston
andrea.schievella@cancer.org.uk



George Tzircotis
Head of Business Development, Cancer Research Horizons Europe
george.tzircotis@cancer.org.uk

